HIV診断薬の世界市場：市場規模・シェア・動向分析 (製品別・モード別・検査の種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

HIV診断薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のHIV診断薬の市場規模は、2025年から2030年にかけてCAGR 5.0%で拡大し、2030年には15億5,000万米ドルに達すると推定されています。

この市場成長の主な要因としては、資源が限られた環境において、患者の治療現場で容易に実施できる、より感度の高いHIV診断POC検査の開発ニーズの高まりが挙げられます。予測期間を通じて多数の新規迅速POC検査が導入されることが期待される検査技術の開発は、HIV診断薬市場の成長を促進する主な要因です。さらに、HIVに対して開始された政府プログラムやキャンペーン、疾病罹患率を低下させるための世界の医療への取り組み、市場の中東および東部地域における高いアンメットニーズの存在は、将来の成長機会として有利に働くと期待されるいくつかの主要因です。

HIV診断薬市場：分析概要

• 抗体検査分野が業界を支配し、2024年には56.6%の最大収益シェアを占めました。この大きなシェアは、ELISA、ホームアクセス乾燥血液スポット、ウェスタンブロット検査IFA、RIPAを含むこれらの検査の高い市場使用率と普及率によって説明できます。これらの検査は高感度で正確であるため、HIV-1およびHIV-2のスクリーニングと確認に最も一般的に使用されています。
• ウイルス負荷検査とCD4検査も、2024年の市場でかなりのシェアを占めています。これらの検査は、より感度が高く、迅速で、POC (ポイントオブケア) に持ち運び可能であるため、資源が乏しいHIV感染地域における市場での有用性とアクセシビリティを高めることができます。
• 予測期間中に、現在臨床開発中で、主要企業の製品パイプラインにある、多くの新規のPOC HIV診断薬製品が商業化されると予想されます。このような製品の増加は、予測期間中の同市場の成長を促進すると予想されます。
• アジア太平洋地域のHIV診断薬業界は、予測期間中に顕著な成長率を示すと予想されます。同地域における研究開発の進展がHIV診断薬市場の重要な促進要因となっています。
• ラテンアメリカのHIV診断薬市場は、予測期間を通じて著しい成長が見込まれます。HIV診断薬市場を牽引しているのは、同地域におけるHIV関連死の減少であり、過去10年間でラテンアメリカでは28%、カリブ海地域では57%減少しています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 HIV診断薬市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• HIV診断薬市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 HIV診断薬市場：製品別の推定・動向分析

• 市場シェア：製品別 (2024年・2030年)
• セグメントダッシュボード
• 世界のHIV診断薬市場：製品別の見通し
• 市場規模の予測と動向分析 (2018～2030年)
  • 消耗品
  • 機器
  • ソフトウェアとサービス

第5章 HIV診断薬市場：モード別の推定・動向分析

• 市場シェア：モード別 (2024年・2030年)
• セグメントダッシュボード
• 世界のHIV診断薬市場：モード別の見通し
• 市場規模の予測と動向分析 (2018～2030年)
  • セルフテスト
  • ラボベース

第6章 HIV診断薬市場：検査の種類別の推定・動向分析

• 市場シェア：検査の種類別 (2024年・2030年)
• セグメントダッシュボード
• 世界のHIV診断薬市場：検査の種類別の見通し
• 市場規模の予測と動向分析 (2018～2030年)
  • 抗体検査
  • ウイルス量検査
  • CD4検査
  • その他

第7章 HIV診断薬市場：最終用途別の推定・動向分析

• 市場シェア：最終用途別 (2024年・2030年)
• セグメントダッシュボード
• 世界のHIV診断薬市場：最終用途別の見通し
• 市場規模の予測と動向分析 (2018～2030年)
  • 診断検査室
  • 病院・診療所
  • 在宅医療

第8章 HIV診断薬市場：地域別の推定・動向分析

• 市場シェア：地域別 (2024年・2030年)
• セグメントダッシュボード
• 世界のHIV診断薬市場：地域別の見通し
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 最近の動向と影響分析：主要な市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア (2024年)
  • Alere Inc.
  • Abbott
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck &Co. Inc.
  • VIIV Healthcare
  • BD
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Apogee Flow Systems
  • Point Care
  • Zyomtronix, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • QIAGEN

List of Tables

• Table 1 List of Abbreviation
• Table 2 North America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 3 North America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 4 North America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 5 North America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 8 U.S HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 9 U.S HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 10 Canada HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 11 Canada HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 12 Canada HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 13 Canada HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 14 Mexico HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 15 Mexico HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 16 Mexico HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 17 Mexico HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 18 Europe HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 19 Europe HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 20 Europe HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 21 Europe HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 22 UK HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 23 UK HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 24 UK HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 25 UK HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 26 Germany HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 27 Germany HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 28 Germany HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 29 Germany HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 30 France HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 31 France HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 32 France HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 33 France HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 34 Italy HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 35 Italy HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 36 Italy HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 37 Italy HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 38 Spain HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 39 Spain HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 40 Spain HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 41 Spain HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 42 Denmark HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 43 Denmark HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 44 Denmark HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 45 Denmark HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 46 Sweden HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 47 Sweden HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 48 Sweden HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 49 Sweden HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 50 Norway HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 51 Norway HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 52 Norway HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 53 Norway HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 58 Japan HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 59 Japan HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 60 Japan HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 61 Japan HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 62 China HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 63 China HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 64 China HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 65 China HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 66 India HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 67 India HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 68 India HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 69 India HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 70 Australia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 71 Australia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 72 Australia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 73 Australia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 74 Thailand HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 75 Thailand HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 76 Thailand HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 77 Thailand HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 78 South Korea HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 79 South Korea HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 80 South Korea HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 81 South Korea HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 82 Latin America HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 83 Latin America HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 84 Latin America HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 85 Latin America HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 86 Brazil HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 87 Brazil HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 88 Brazil HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 89 Brazil HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 90 Argentina HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 91 Argentina HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 92 Argentina HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 93 Argentina HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 94 Middle East & Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 95 Middle East & Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 96 Middle East & Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 97 Middle East & Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 98 South Africa HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 99 South Africa HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 100 South Africa HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 101 South Africa HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 102 Saudi Arabia HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 103 Saudi Arabia HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 104 Saudi Arabia HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 105 Saudi Arabia HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 106 UAE HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 107 UAE HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 108 UAE HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 109 UAE HIV diagnostics market, by end use, 2018 - 2030 (USD Million)
• Table 110 Kuwait HIV diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 111 Kuwait HIV diagnostics market, by mode, 2018 - 2030 (USD Million)
• Table 112 Kuwait HIV diagnostics market, by test type, 2018 - 2030 (USD Million)
• Table 113 Kuwait HIV diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 HIV Diagnostics: Market outlook
• Fig. 9 HIV Diagnostics: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 HIV Diagnostics Market driver impact
• Fig. 15 HIV Diagnostics Market restraint impact
• Fig. 16 HIV Diagnostics Market strategic initiatives analysis
• Fig. 17 HIV Diagnostics market: Product movement analysis
• Fig. 18 HIV Diagnostics market: Product outlook and key takeaways
• Fig. 19 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Software and Services market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 HIV Diagnostics market: Mode movement analysis
• Fig. 23 HIV Diagnostics market: Mode outlook and key takeaways
• Fig. 24 Self-test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Lab-based market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 HIV Diagnostics market: Test type movement analysis
• Fig. 27 HIV Diagnostics market: Test type outlook and key takeaways
• Fig. 28 Antibody Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 HIV-1 Screening Tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 ELISA/EIA market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Home Access Dried Blood Spot market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Rapid Tests (Dot plot, Agglutination Tests) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 HIV-1 Antibody Confirmatory Tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Western Blot Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Indirect Immunofluorescent Antibody Assay (IFA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Line Immunoassay market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 RadioImmunoPrecipitation Assay (RIPA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 HIV-2 & Group O Diagnostic Tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Blood Antibody Tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Dried Blood Spot (DBS) Test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Others and (Oral, Urine) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Viral load test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 CD4 test market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 HIV Diagnostics market: End Use movement analysis
• Fig. 46 HIV Diagnostics market: End Use outlook and key takeaways
• Fig. 47 Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Hospitals & Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Home Settings market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 North America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 U.S HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Canada HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Mexico HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Europe HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 UK HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Germany HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 France HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Italy HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Spain HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Sweden HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Norway HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Denmark HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Asia Pacific HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Japan HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 China HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 India HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Australia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Thailand HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 South Korea HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Latin America HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Brazil HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Argentina HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Middle East and Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Saudi Arabia HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 South Africa HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 UAE HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Kuwait HIV diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)

HIV Diagnostics Market Growth & Trends:

The global HIV diagnostics market size is estimated to reach USD 1.55 billion by 2030, expanding at a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

HIV Diagnostics Market Report Highlights:

• The antibody test segment dominated the industry and accounted for the largest revenue share of 56.6% in 2024. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA, and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
• Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2024. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature, and portable to the point of care to enhance their market usability and accessibility in resource-limited HIV-affected regions.
• It is expected that during the forecast period, a number of novel point-of-care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the forecast period.
• The Asia Pacific HIV diagnostics industry is expected to experience a notable growth rate during the forecast period. Advancements in research and development in the region are significant drivers for the HIV diagnostics market.
• The Latin America HIV diagnostics industry is expected to experience significant growth throughout the forecast period. The HIV diagnostics market is driven by the region's progress in reducing HIV-related deaths, which have declined by 28% in Latin America and 57% in the Caribbean over the past decade.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mode
  • 1.2.3. Test Type
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Mode outlook
  • 2.2.3. Test type outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. HIV Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in Diagnostic Technologies
    • 3.2.1.2. Government Initiatives to Increase Accessibility
    • 3.2.1.3. Rising HIV Awareness and Screening Programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Diagnostics
    • 3.2.2.2. Stigma and Social Barriers
• 3.3. HIV Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. HIV Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global HIV Diagnostics Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Consumables
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Software and Services
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Diagnostics Market: Mode Estimates & Trend Analysis

• 5.1. Mode Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global HIV Diagnostics Market by Mode Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Self-test
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Lab-based
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Diagnostics Market: Test Type Estimates & Trend Analysis

• 6.1. Test Type Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global HIV Diagnostics Market by Test Type Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Antibody Test
    • 6.4.1.1. HIV-1 Screening Tests
      • 6.4.1.1.1. ELISA/EIA
        • 6.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.1.2. Home Access Dried Blood Spot
        • 6.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.2.2. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.1.3. Rapid Tests (Dot plot, Agglutination Tests)
        • 6.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.1.2. HIV-1 Antibody Confirmatory Tests
      • 6.4.1.2.1. Western Blot Test
        • 6.4.1.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.2. Indirect Immunofluorescent Antibody Assay (IFA)
        • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.3. Line Immunoassay
        • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.4. RadioImmunoPrecipitation Assay (RIPA)
        • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.1.3. HIV-2 & Group O Diagnostic Tests
      • 6.4.1.3.1. Blood Antibody Tests
        • 6.4.1.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3.2. Dried Blood Spot (DBS) Test
        • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3.3. Others and (Oral, Urine)
        • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Viral load test
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.3. CD4 test
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.4. Others
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. HIV Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global HIV Diagnostics Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Diagnostic Laboratories
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. Hospitals & Clinics
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.3. Home Settings
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. HIV Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Target disease prevalence
    • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Target disease prevalence
    • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Target disease prevalence
    • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Target disease prevalence
    • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Target disease prevalence
    • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Target disease prevalence
    • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Target disease prevalence
    • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Target disease prevalence
    • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Target disease prevalence
    • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Target disease prevalence
    • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Target disease prevalence
    • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Target disease prevalence
    • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Target disease prevalence
    • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Target disease prevalence
    • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Target disease prevalence
    • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Target disease prevalence
    • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Target disease prevalence
    • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Target disease prevalence
    • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.1.6. )
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Target disease prevalence
    • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. Target disease prevalence
    • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Target disease prevalence
    • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Target disease prevalence
    • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Target disease prevalence
    • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Alere Inc.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Abbott
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Bristol-Myers Squibb Company
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Janssen Global Services, LLC
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Gilead Sciences, Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Merck & Co. Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. VIIV Healthcare
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. BD
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Beckman Coulter, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Sysmex Europe SE
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Apogee Flow Systems
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Point Care
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Zyomtronix, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Mylan N.V.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. F. Hoffmann-La Roche Ltd.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Siemens Healthcare GmbH
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. QIAGEN
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Product benchmarking
    • 9.3.18.4. Strategic initiatives